Year in Review 2024 - Key Updates in Melanoma Treatment

Oncology 2024 Year in Review

T. Haykal

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

The Latest and Greatest in Melanoma Treatment, 2024: From Adjuvant t…

Melanoma Research Foundation

K. Margolin

Understanding TIL Cell Therapy and the Patient Journey for Advanced …

Melanoma Research Foundation

J. Lutzky

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

Medical Treatments for Melanoma: Current and Future Options

Melanoma Research Foundation

F. Collichio

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

Role of Nivolumab/Relatlimab in the 1L Treatment Landscape for Metas…

Rodabe Amaria

Optimal Therapy Sequence for 1L Treatment of BRAF-Mutated Metastatic…

Stanford Medicine

A. Betof Warner

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

Triumphs and Challenges in Treating Unresectable Melanoma

Melanoma Research Foundation

H. Kluger

Efficacy of Nivo and Relatlimab as 1L Therapy for Metastatic Melanom…

Gabriela Cinat

Understanding Treatment Sequencing in Metastatic Melanoma: IO vs. Ta…

Vanderbilt University Medical Center (VUMC)

D. Johnson